Guggenheim analyst Vamil Divan lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $37 from $40 and keeps a Buy rating on the shares. The firm trimmed its target, driven by higher operating expenses and a higher share count, but notes that the company continues to be on track for potential FDA approval of oxylanthanum carbonate on its upcoming June 29 PDUFA deadline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
- Unicycive Therapeutics initiated with a Buy at B. Riley
- Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark
- Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim
- UNCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?